The United States Patent and Trademark Office (USPTO) has published patent application US20260085115A1, titled 'CD3 BINDING ANTIBODIES'. The application, filed on June 2, 2025, lists five inventors and describes human CD3 antigen-binding polypeptides and their preparation and use in treating and diagnosing diseases, as well as bispecific antibody molecules for activating immune effector cells.

This publication is a notice of a new patent application and does not impose new regulatory obligations. Companies involved in the development or research of CD3 binding antibodies or related bispecific antibody technologies should be aware of this intellectual property filing. No immediate compliance actions are required, but it may inform R&D strategies and competitive landscape analysis.